| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2008 | WO2008074803A3 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists |
| 09/18/2008 | WO2008073304A9 Cancer treatment methods |
| 09/18/2008 | WO2008070602A3 Topical pharmaceutical composition |
| 09/18/2008 | WO2008070496A3 N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| 09/18/2008 | WO2008070463A9 Endoxifen methods and compositions |
| 09/18/2008 | WO2008063232B1 Substituted pyrazolopyrimidines |
| 09/18/2008 | WO2008062453A3 Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form |
| 09/18/2008 | WO2008061625A3 Transdermal therapeutic system for administering the active substance buprenorphine |
| 09/18/2008 | WO2008060332A8 Methods for treating or reducing muscle fatigue |
| 09/18/2008 | WO2008059014A3 Antituberculosis agents with alkylidene or alkyl side chain |
| 09/18/2008 | WO2008058697A3 Sorption medium |
| 09/18/2008 | WO2008057336A3 Heterocyclyl-substituted anti-hypercholesterolemic compounds |
| 09/18/2008 | WO2008049842A3 Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders |
| 09/18/2008 | WO2008048981A3 Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 09/18/2008 | WO2008043024A3 Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| 09/18/2008 | WO2008036967A3 Novel heterocyclic compounds as lasy activators |
| 09/18/2008 | WO2008033956A9 Macrocyclic lactone compounds and methods for their use |
| 09/18/2008 | WO2008033543A3 Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment |
| 09/18/2008 | WO2008033444A3 Anti-apoptotic benzodiazepine receptor ligand inhibitors |
| 09/18/2008 | WO2008031831A3 Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein |
| 09/18/2008 | WO2008028097A3 Method for skin care |
| 09/18/2008 | WO2008022345A3 Compositions and methods for inhibiting cytochrome p450 |
| 09/18/2008 | WO2008020039A3 2,5-dihydroxybenzene compounds for treating cancers and hematological dyscrasias |
| 09/18/2008 | WO2008019139A3 Inhibitors of pyruvate kinase and methods of treating disease |
| 09/18/2008 | WO2008011363A3 Quercetin-containing compositions |
| 09/18/2008 | WO2008011126A3 Liquid compositions of calcium acetate |
| 09/18/2008 | WO2008002121A3 A self-emulsifying composition for poorly bioavailable drugs |
| 09/18/2008 | WO2007147052A3 Topical compositions |
| 09/18/2008 | WO2007145938A3 Beverages containing pheromone component |
| 09/18/2008 | WO2007140022A3 Fucoidan compositions and methods |
| 09/18/2008 | WO2007123995A3 Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same |
| 09/18/2008 | WO2007104933A8 Chemical compounds |
| 09/18/2008 | WO2007103373A3 Compositions and methods for the treatment of immunoinflammatory disorders |
| 09/18/2008 | WO2007100910A3 Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods |
| 09/18/2008 | WO2007090068A3 Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| 09/18/2008 | WO2007014012A3 Compositions and methods for wood preservation |
| 09/18/2008 | WO2007003386A9 Imidazopyridine derivatives as acid pump antagonists |
| 09/18/2008 | US20080229435 Using mitogen activated kinase as tool in identifying modulators for treatment and prevention of cell proliferative disorders |
| 09/18/2008 | US20080228151 Transdermal drug delivery with controlled heat for treating musculoskeletal pain and/or inflammation |
| 09/18/2008 | US20080228005 Polymorphs of suberoylanilide hydroxamic acid |
| 09/18/2008 | US20080227983 Piperidine derivatives and process for their production |
| 09/18/2008 | US20080227870 Contacting cells with a carcinogen-extracting solvent of a perfluorocarbon liquid such as perfluorodecalin, perfluorooctyl bromide or a Fluorinet" liquid; biocompatability; prophylactically reducing the risk of cancerous cell transformation; lipophilic to dissolve from cell membrane |
| 09/18/2008 | US20080227869 Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof |
| 09/18/2008 | US20080227868 Composition Comprising an Hdac Inhibitor in Combination with a Retinoid |
| 09/18/2008 | US20080227867 Use of 4-hydroxychalcone derivatives for masking an upleasant taste |
| 09/18/2008 | US20080227866 Hydroxyphenylalkadiones and Their Use for Masking Bitter Taste and/or for Intensifying Sweet Taste |
| 09/18/2008 | US20080227865 Reducing digestion of lipids to treat or prevent obesity by administering an acyclic amine optionally containing ether groups or a sulfide group, e.g., 2-(Dimethylamino)ethyl stearyl ether, N,N-dimethylhexadecylamine, or 2-(Diisopropylamino)ethyl dodecyl ether |
| 09/18/2008 | US20080227864 Lhr1 Activators as Medicaments |
| 09/18/2008 | US20080227863 Such as N-[2-(2-Chloro-phenoxy)-1,1-dicyano-ethyl]-4-trifluoromethoxy-benzamide for controlling parasites in and on warm-blooded animals |
| 09/18/2008 | US20080227862 histone deacetylase (HDAC) inhibitor useful in selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells; have a high bioavailability and gives high blood levels of the active compounds over a long time |
| 09/18/2008 | US20080227861 Inhibition of Allergic Contact Dermatitis By N-L-ALPHA-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER |
| 09/18/2008 | US20080227860 Composition Comprising Oleic Acid and the Use Thereof |
| 09/18/2008 | US20080227859 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 09/18/2008 | US20080227858 as collagenase 1, 2 and 3, gelatinase A and B, stromelysin 1, 2 and 3, matrilysin, macrophage metalloelastase, enamelysin and membrane type 1, 2, 3 and 4 MMP; [(4'-Cyano-1,1'-biphenyl-4-yl)(methylsulfonyl)amino]acetic acid; antiinflammatory, anticarcinogenic agent, neurodegenerative diseases |
| 09/18/2008 | US20080227857 N-Alkylcarbonyl-Amino Acid Ester and N-Alkylcarbonyl-Amino Lactone Compounds and Their Use |
| 09/18/2008 | US20080227855 Bridging component (polyhydroxypropylmethacrylate and/or polyacrylic acid) forms hydrogen bonds with both biodrug (griseofulvin) and carrier (polyvinypyrrolidone), which decreases tendency to crystallise; evaporation, spray drying |
| 09/18/2008 | US20080227854 anti-inflammatory compound 3-(1,1-dimethyl-allyl)-6-hydroxy-chromen-2-one isolated from the Ruta graveolens L. plant for the inhibition of inos gene thereby reducing nitric oxide level that increases significantly in inflammatory diseases |
| 09/18/2008 | US20080227853 Administering catechin, epicatechin, and derivatives thereof; apoptosis; cancer; microencapsulation |
| 09/18/2008 | US20080227852 such as: 3-Deoxyschweinfurthin B; anticancer assay; e.g. breast cancer or a cancer of the CNS or renal system diagnosis |
| 09/18/2008 | US20080227851 psoriasis, eczema, multiple sclerosis, and arthritis; cross-metathesis reaction being promoted by a cross-metathesis catalyst |
| 09/18/2008 | US20080227850 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 09/18/2008 | US20080227849 Formed by direct powder compression of mixture containing granular sugar alcohol and povidone-iodine; not subjected to wet granulation |
| 09/18/2008 | US20080227848 Identifying agent which modulates 2-oxoglutarate dependent oxygenase; ankyrin substrate; hypoxia-inducible factor; thalassemia |
| 09/18/2008 | US20080227847 (S)-2-hydro-2,6-diaminohexanal-(E)-methoxy-4-oxobut-2-enoate(lysine monomethylfumarate); treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders |
| 09/18/2008 | US20080227846 Administering competitive inhibitor of mevalonate synthesis, competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (such as statin), or inducer of AMP protein kinase (AMPK) activity; sustained release |
| 09/18/2008 | US20080227845 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 09/18/2008 | US20080227844 evaluating bucindolol treatment for patient with heart failure; whether to administer bucindolol based on if the patient is homozygous for the Arg 389 polymorphism in the .beta.1-adrenergic receptor; bucindolol not indicated wherein the patient is a Del322-325 carrier in alpha2cAR; pharmacogenetics |
| 09/18/2008 | US20080227843 Therapeutic use of n-(1h-indolyl)-1h-indole-2-carboxamide derivatives |
| 09/18/2008 | US20080227842 Non-fluorescent chlorophyll catabolites |
| 09/18/2008 | US20080227841 Intravesical apaziquone administration following transurethral resection |
| 09/18/2008 | US20080227839 Kinase Inhibitors |
| 09/18/2008 | US20080227838 Method for neuroprotection with glycoluril derivatives |
| 09/18/2008 | US20080227837 Novel Compounds |
| 09/18/2008 | US20080227836 Stable Solid Oral Dosage Forms of Valsartan |
| 09/18/2008 | US20080227834 Derivatives of 2-aminothiazoles and 2-amino-oxazoles, processes for their preparation and their use as pharmaceutical compositions |
| 09/18/2008 | US20080227833 Selective inhibitors of MMP-9 and/or MMP12; antiinflammatory agents for multiple sclerosis and fibrosis; 3R-[2,2-Dimethyl-1 S-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propylcarbamoyl]-2S-hydroxy-5-methyl-hexanohydroxamic acid; bone resorption, metastases, rheumatoid arthritis, Crohn's disease |
| 09/18/2008 | US20080227832 Contains nicotinic acid compound, Maillard reaction product and/or metabolite thereof; reduces blood lipid levels |
| 09/18/2008 | US20080227831 Contains N-methylnicotinamide; seaweed extracts; atherosclerosis |
| 09/18/2008 | US20080227830 For reduction of dizziness, fainting, lightheadedness, fatigue, muscle aches, headaches, confusion, and nausea; kits |
| 09/18/2008 | US20080227829 for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; apigenin; acacetin; luteolin |
| 09/18/2008 | US20080227828 Aryl Ureas With Angiogenisis Inhibiting Activity |
| 09/18/2008 | US20080227827 Compounds that abrogate dna damage induced cell cycle g2 checkpoint and/or augment anti-cancer activity of dna-damaging treatments |
| 09/18/2008 | US20080227826 Such as (S)-2-(Dimethylamino)ethyl-1-(4-(2-aminophenylcarbamoyl)-phenyl)pyrrolidin-3-ylcarbamate for treating cell proliferative disorders |
| 09/18/2008 | US20080227825 Dipeptidylpeptidase IV inhibitors such as vildagliptin and metformin; tablets |
| 09/18/2008 | US20080227824 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders |
| 09/18/2008 | US20080227823 (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity |
| 09/18/2008 | US20080227822 Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i |
| 09/18/2008 | US20080227821 N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors |
| 09/18/2008 | US20080227820 cis-6-Fluoro-1-{[1-(4-fluorophenyl)-1H-indazol-4-yl]amino}-1,2,3,4-tetrahydro-5-methoxy-4,4-dimethyl-6-(trifluoromethyl)naphthalene-2-ol; selectivity towards the glucocorticoid receptor (GR) is improved compared to the other steroid receptors |
| 09/18/2008 | US20080227819 Method for identifying the agonistic activity of a target compound on a potassium channel |
| 09/18/2008 | US20080227818 Neurokinin A receptor antagonist |
| 09/18/2008 | US20080227817 N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide benzoate; used to inhibit Chemokine Receptor 1 in treating airways disease such as chronic obstructive pulmonary disease and asthma |
| 09/18/2008 | US20080227816 Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| 09/18/2008 | US20080227815 Crystal of Indole Derivative Having Piperidine Ring and Process for Production Thereof |
| 09/18/2008 | US20080227814 Ethanolamine derivatives such as 6-hydroxy-1-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-(p-methylsulfonylphenyl)tetralin and 6-hydroxy-2-(p-(trifluoromethyl)phenyl)-3-(p-(2-(1-piperidinyl)ethoxy)benzoyl)benzothiophene; treating endometriosis and uterine leiomyoma. |
| 09/18/2008 | US20080227813 Mixture of a C-disubstituted-O-substituted oxime, e.g., N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride another drug (riluzole), and a carrier; treating amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's Disease, stroke and cystic fibrosis. |
| 09/18/2008 | US20080227812 Spiro Substituted Compounds As Angiogenesis Inhibitors |
| 09/18/2008 | US20080227811 Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases |
| 09/18/2008 | US20080227810 6-Cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| 09/18/2008 | US20080227809 hexaquis(3-phenyl-propylamine) decavanadate (V); particularly insulin-resistant diabetes; insulin mimickers |